Cogent (COGT) Reiterated at Buy by Stifel After ASCO Presentation on Bezuclastinib
Tweet Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $45.00 price target on Cogent (NASDAQ: COGT).The analyst commented, " At ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
